Anticipatory nausea and vomiting in an ambulatory medical oncology population

John H Fetting, P. M. Wilcox, B. A. Iwata, E. L. Criswell, L. S. Bosmajian, V. R. Sheidler

Research output: Contribution to journalArticle

Abstract

We studied the prevalence of anticipatory nausea (AN) and anticipatory nausea and vomiting (ANV) in an ambulatory medical oncology population by self-report questionnaire over 7 weeks. Thirty-eight of 123 (31%) patients receiving parenteral chemotherapy reported anticipatory symptoms (AN or ANV). Twenty-one (17%) patients reported ANV and 17 (14%) reported AN only. Patients receiving parenteral chemotherapy (N = 123) with anticipatory symptoms (N = 38) were younger (45.1 ± SE 1.9 vs 55.5 ± 1.45, P <0.001) and more likely to be female (82% vs 61%, P = 0.04), unmarried (47% vs 26%, P = 0.03), and receiving adjuvant chemotheray for breast cancer (42% vs 7% P <0.001) than patients without anticipatory symptoms (N = 85). A greater proportion of patients with both postchemotherapy nausea and vomiting and anticipatory symptoms reported > 12 hours of postchemotherapy nausea (65% vs 39%, P = 0.01) and postchemotherapy nausea and vomiting (37% vs 12%, P = 0.01) after their most recent cycle of chemotherapy than did patients with postchemotherapy symptoms only. In structured interviews with 23 patients with anticipatory symptoms, 16 identified specific stimuli associated with AN and ANV, taste being the most frequently mentioned (ten of 16 patients) sensory modality. In our clinic, patients receiving adjuvant chemotherapy for breast cancer develop anticipatory symptoms frequently and represent a relatively homogenous sample for further studies.

Original languageEnglish (US)
Pages (from-to)1093-1098
Number of pages6
JournalCancer Treatment Reports
Volume67
Issue number12
StatePublished - 1983

Fingerprint

Anticipatory Vomiting
Medical Oncology
Nausea
Population
Drug Therapy
Adjuvant Chemotherapy
Self Report
Vomiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fetting, J. H., Wilcox, P. M., Iwata, B. A., Criswell, E. L., Bosmajian, L. S., & Sheidler, V. R. (1983). Anticipatory nausea and vomiting in an ambulatory medical oncology population. Cancer Treatment Reports, 67(12), 1093-1098.

Anticipatory nausea and vomiting in an ambulatory medical oncology population. / Fetting, John H; Wilcox, P. M.; Iwata, B. A.; Criswell, E. L.; Bosmajian, L. S.; Sheidler, V. R.

In: Cancer Treatment Reports, Vol. 67, No. 12, 1983, p. 1093-1098.

Research output: Contribution to journalArticle

Fetting, JH, Wilcox, PM, Iwata, BA, Criswell, EL, Bosmajian, LS & Sheidler, VR 1983, 'Anticipatory nausea and vomiting in an ambulatory medical oncology population', Cancer Treatment Reports, vol. 67, no. 12, pp. 1093-1098.
Fetting JH, Wilcox PM, Iwata BA, Criswell EL, Bosmajian LS, Sheidler VR. Anticipatory nausea and vomiting in an ambulatory medical oncology population. Cancer Treatment Reports. 1983;67(12):1093-1098.
Fetting, John H ; Wilcox, P. M. ; Iwata, B. A. ; Criswell, E. L. ; Bosmajian, L. S. ; Sheidler, V. R. / Anticipatory nausea and vomiting in an ambulatory medical oncology population. In: Cancer Treatment Reports. 1983 ; Vol. 67, No. 12. pp. 1093-1098.
@article{4373c40355f44044bd0f4b448eefe079,
title = "Anticipatory nausea and vomiting in an ambulatory medical oncology population",
abstract = "We studied the prevalence of anticipatory nausea (AN) and anticipatory nausea and vomiting (ANV) in an ambulatory medical oncology population by self-report questionnaire over 7 weeks. Thirty-eight of 123 (31{\%}) patients receiving parenteral chemotherapy reported anticipatory symptoms (AN or ANV). Twenty-one (17{\%}) patients reported ANV and 17 (14{\%}) reported AN only. Patients receiving parenteral chemotherapy (N = 123) with anticipatory symptoms (N = 38) were younger (45.1 ± SE 1.9 vs 55.5 ± 1.45, P <0.001) and more likely to be female (82{\%} vs 61{\%}, P = 0.04), unmarried (47{\%} vs 26{\%}, P = 0.03), and receiving adjuvant chemotheray for breast cancer (42{\%} vs 7{\%} P <0.001) than patients without anticipatory symptoms (N = 85). A greater proportion of patients with both postchemotherapy nausea and vomiting and anticipatory symptoms reported > 12 hours of postchemotherapy nausea (65{\%} vs 39{\%}, P = 0.01) and postchemotherapy nausea and vomiting (37{\%} vs 12{\%}, P = 0.01) after their most recent cycle of chemotherapy than did patients with postchemotherapy symptoms only. In structured interviews with 23 patients with anticipatory symptoms, 16 identified specific stimuli associated with AN and ANV, taste being the most frequently mentioned (ten of 16 patients) sensory modality. In our clinic, patients receiving adjuvant chemotherapy for breast cancer develop anticipatory symptoms frequently and represent a relatively homogenous sample for further studies.",
author = "Fetting, {John H} and Wilcox, {P. M.} and Iwata, {B. A.} and Criswell, {E. L.} and Bosmajian, {L. S.} and Sheidler, {V. R.}",
year = "1983",
language = "English (US)",
volume = "67",
pages = "1093--1098",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Anticipatory nausea and vomiting in an ambulatory medical oncology population

AU - Fetting, John H

AU - Wilcox, P. M.

AU - Iwata, B. A.

AU - Criswell, E. L.

AU - Bosmajian, L. S.

AU - Sheidler, V. R.

PY - 1983

Y1 - 1983

N2 - We studied the prevalence of anticipatory nausea (AN) and anticipatory nausea and vomiting (ANV) in an ambulatory medical oncology population by self-report questionnaire over 7 weeks. Thirty-eight of 123 (31%) patients receiving parenteral chemotherapy reported anticipatory symptoms (AN or ANV). Twenty-one (17%) patients reported ANV and 17 (14%) reported AN only. Patients receiving parenteral chemotherapy (N = 123) with anticipatory symptoms (N = 38) were younger (45.1 ± SE 1.9 vs 55.5 ± 1.45, P <0.001) and more likely to be female (82% vs 61%, P = 0.04), unmarried (47% vs 26%, P = 0.03), and receiving adjuvant chemotheray for breast cancer (42% vs 7% P <0.001) than patients without anticipatory symptoms (N = 85). A greater proportion of patients with both postchemotherapy nausea and vomiting and anticipatory symptoms reported > 12 hours of postchemotherapy nausea (65% vs 39%, P = 0.01) and postchemotherapy nausea and vomiting (37% vs 12%, P = 0.01) after their most recent cycle of chemotherapy than did patients with postchemotherapy symptoms only. In structured interviews with 23 patients with anticipatory symptoms, 16 identified specific stimuli associated with AN and ANV, taste being the most frequently mentioned (ten of 16 patients) sensory modality. In our clinic, patients receiving adjuvant chemotherapy for breast cancer develop anticipatory symptoms frequently and represent a relatively homogenous sample for further studies.

AB - We studied the prevalence of anticipatory nausea (AN) and anticipatory nausea and vomiting (ANV) in an ambulatory medical oncology population by self-report questionnaire over 7 weeks. Thirty-eight of 123 (31%) patients receiving parenteral chemotherapy reported anticipatory symptoms (AN or ANV). Twenty-one (17%) patients reported ANV and 17 (14%) reported AN only. Patients receiving parenteral chemotherapy (N = 123) with anticipatory symptoms (N = 38) were younger (45.1 ± SE 1.9 vs 55.5 ± 1.45, P <0.001) and more likely to be female (82% vs 61%, P = 0.04), unmarried (47% vs 26%, P = 0.03), and receiving adjuvant chemotheray for breast cancer (42% vs 7% P <0.001) than patients without anticipatory symptoms (N = 85). A greater proportion of patients with both postchemotherapy nausea and vomiting and anticipatory symptoms reported > 12 hours of postchemotherapy nausea (65% vs 39%, P = 0.01) and postchemotherapy nausea and vomiting (37% vs 12%, P = 0.01) after their most recent cycle of chemotherapy than did patients with postchemotherapy symptoms only. In structured interviews with 23 patients with anticipatory symptoms, 16 identified specific stimuli associated with AN and ANV, taste being the most frequently mentioned (ten of 16 patients) sensory modality. In our clinic, patients receiving adjuvant chemotherapy for breast cancer develop anticipatory symptoms frequently and represent a relatively homogenous sample for further studies.

UR - http://www.scopus.com/inward/record.url?scp=0021034080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021034080&partnerID=8YFLogxK

M3 - Article

C2 - 6652626

AN - SCOPUS:0021034080

VL - 67

SP - 1093

EP - 1098

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -